CardioExchange Archive

December 29th, 2011

J&J Applies for ACS Indication for Rivaroxaban (Xarelto)

Larry Husten, PHD

Based on the promising results of the recently published ATLAS ACS 2 TIMI 51 trial, Johnson & Johnson has submitted a supplemental new drug application to the FDA for the approval of rivaroxaban (Xarelto) to reduce the risk of thrombotic cardiovascular events in ACS patients. Following a succession of failed trials, ATLAS was the first trial to […]

---

November 13th, 2011

ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients

Larry Husten, PHD

Results of the highly anticipated ATLAS-ACS 2–TIMI 51 trial demonstrate that ACS patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor Xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome  trial was […]

---

November 13th, 2011

TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS

Larry Husten, PHD

The novel antiplatelet vorapaxar, which blocks the thrombin receptor to inhibit platelet activation, ran into trouble in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, which was stopped prematurely earlier this year due to safety concerns. TRACER was presented at the AHA by Ken Mahaffey and published simultaneously in the New England Journal of Medicine. […]

---

September 29th, 2011

Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51

Larry Husten, PHD

Bayer AG announced today that in the ATLAS ACS TIMI 51 trial, rivaroxaban (Xarelto, Bayer and Johnson & Johnson) had met the primary efficacy endpoint  in patients with acute coronary syndrome (ACS). The drug was associated with “a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction […]

---

August 30th, 2011

Intra-Aortic Balloon Counterpulsation (IABP) Burned to a CRISP

Richard A. Lange, MD, MBA and L. David Hillis, MD

Intra-aortic balloon counterpulsation (IABP) is a bust in AMI patients without cardiogenic shock, according to the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction (CRISP AMI) trial. This open-label, 30-center, randomized, controlled trial was performed to determine if a routine strategy of IABP before primary PCI (and continued for at least 12 hours afterward) would […]

---

July 25th, 2011

Panel: Will You Prescribe Ticagrelor (Brilinta)?

CardioExchange Editors, Staff

Three experts discuss whether — and with which patients — they will use ticagrelor in clinical practice.

---

July 24th, 2011

APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS

Larry Husten, PHD

A large phase 3 trial of an investigational factor Xa inhibitor, when added to antiplatelet therapy in ACS patients, was stopped early because of bleeding complications.

---

June 27th, 2011

Asprin Dosage in U.S. May Explain Disparity in Ticagrelor Results in PLATO

Larry Husten, PHD

Although the PLATO trial demonstrated the overall superiority of ticagrelor (Brilinta, AstraZeneca) to clopidogrel in more than 18,000 acute coronary syndrome patients worldwide, approval of the drug in the U.S. has been delayed because of ticagrelor’s lack of effect in the prespecified subgroup of patients from North America. Now, two analyses of the trial, presented […]

---

May 13th, 2011

Simultaneous TIA and ACS After Aspirin Cessation for Palpebral Surgery

Jean-Pierre Usdin, MD and James Fang, MD

A 77-year-old man with metformin-treated type 2 diabetes, high blood pressure, moderate renal insufficiency, stable angina, and a history of phlebitis stopped taking aspirin in preparation for palpebral surgery. A day after the surgery, he presented to the ER with two transient ischemic attacks (TIAs) affecting the left arm. The patient complained to the examining neurologist of […]

---

January 19th, 2011

What PROSPECT Doesn’t Tell Us

Richard A. Lange, MD, MBA and L. David Hillis, MD

The PROSPECT trial provides some interesting insights about the mechanisms of thrombotic coronary artery disease, but how, if at all, should it change practice? Here are what the findings do and do not demonstrate: What the PROSPECT study says: In ACS patients treated with PCI, major adverse cardiovascular events that occurred during a median follow-up of 3.4 years were as […]

---